A novel, patient-tailored monoclonal antibody therapy has shown promise in treating moderate to severe atopic dermatitis. Patients who participated in a clinical trial of rocatinlimab showed positive results while taking the drug and up to 20 weeks after stopping therapy, Mount Sinai researchers have… Read More
Biotechnology company Infinimmune has closed a $12 million seed round to focus on human-derived antibody drugs. The seed funding was led by Playground Global, with participation from Pear VC, Civilization Ventures, Axial VC, Ron Alfa, Jacob Becraft, Paul Conley, and Joshua Meier. “The industry has proven the value of antibody-based… Read More
Watch the webinar Harnessing the power of IgE antibodies to create novel therapeutics supported by SPT Labtech. From human B cells to engineered antibodies, IgGenix is taking a novel approach towards breaking through the last frontier of immunology: allergies. By reengineering key antibodies in the allergic cascade, this… Read More
CAR-T therapy can be used to eliminate unwanted cells that cause autoimmunity, according to the results of a new study in mice with an autoimmune disease similar to multiple sclerosis (MS). CAR-T, which uses genetically altered immune cells to destroy cancer cells, has revolutionised treatment of some… Read More
Watch the webinar Harnessing the power of IgE antibodies to create novel therapeutics supported by SPT Labtech. From human B cells to engineered antibodies, IgGenix is taking a novel approach towards breaking through the last frontier of immunology: allergies. By reengineering key antibodies in the allergic cascade, this… Read More
Watch the webinar Harnessing the power of IgE antibodies to create novel therapeutics supported by SPT Labtech. From human B cells to engineered antibodies, IgGenix is taking a novel approach towards breaking through the last frontier of immunology: allergies. By reengineering key antibodies in the allergic cascade, this… Read More
Cancer is supported by complex ecosystems within the body which can be disrupted by cutting-edge new treatments and cures, cancer researchers have concluded. The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust have revealed plans to direct research against the cells, signals and… Read More
This is the latest episode of the free DDW podcast, “The next steps in the fight against cancer”. It covers two articles written for Volume 22, Issue 4 – Fall 2021 of DDW. They are called “Accelerating research: the path forward for treating rare cancers” and “Inside combination… Read More
Triumvira Immunologics has revealed positive clinical data from its ongoing TACTIC‑2 Phase I/II trial of TAC01-HER2 in patients with human epidermal growth factor receptor 2 (HER2) positive solid tumours. These interim data demonstrate that TAC01-HER2 is well-tolerated and clinical activity was observed in the two higher dosing cohorts,… Read More
Watch the webinar Harnessing the power of IgE antibodies to create novel therapeutics supported by SPT Labtech. From human B cells to engineered antibodies, IgGenix is taking a novel approach towards breaking through the last frontier of immunology: allergies. By reengineering key antibodies in the allergic cascade, this biotech… Read More
A new genetically engineered herpes virus has delivered a one-two punch against advanced cancers in initial findings from a Phase I trial. Researchers have found that RP2 – a modified version of the herpes simplex virus – showed signs of effectiveness in a quarter of patients with a range of… Read More
Professor Dr Cornelis (‘Kees’) Melief has been awarded the 2022 Pedro J Romero Service to JITC Award by the Society for Immunotherapy of Cancer (SITC). The Award recognises individuals who have made immeasurable contributions and demonstrated outstanding commitment to the Journal for Immunotherapy of Cancer (JITC) and will be… Read More
A study led by LSU Health New Orleans cancer researchers describes a novel therapeutic strategy to overcome tumour-induced immunosuppression. For the first time, the research team identified a critical immunosuppressive pathway and a promising approach to intervene, protecting the ability of T-cells to attack cancer cells. Results are published in… Read More
Listen to this article on the DDW Podcast: A ground breaking ‘immunoablative’ neoadjuvant immunotherapy clinical trial at Memorial Sloan Kettering Cancer Center (MSK) has reported a 100% complete response rate in MMRd locally advanced rectal cancer. Breakthrough findings were presented at the 2022 ASCO Annual Meeting and… Read More
The size of tumour and immune cell populations and their interactions over time impact outcomes to treatment. Immunotherapies that activate the immune system to seek and kill cancer cells have greatly improved outcomes for many patients with solid tumours. There is still, however, a subset of patients who do not… Read More
Listen to this article on the DDW Podcast: By Courtney Ferrebee, PhD, Field Applications Scientist, Taconic Biosciences. Although immunotherapy has revolutionised cancer therapy, the effectiveness of currently available immunotherapies varies significantly across patients and treatment types. As a result, researchers are striving to continually improve immuno-oncology approaches using the… Read More
